Table 1.
Demographics and characteristics of patients enrolled in this study.
| Characteristics | Total (n = 133) | NDMM (n = 82) | RRMM (n = 51) |
|---|---|---|---|
| Median age (range) | 63 (37–87) | 59 (37–79) | 66 (46–87) |
| Gender | |||
| Male | 78 (58.6%) | 47 (57.3%) | 33 (64.7%) |
| Female | 55 (41.4%) | 35 (42.7%) | 18 (35.3%) |
| Chromosomal abnormalities (%)a | |||
| t (4;14) | 22 (16.5%) | 9 (10.9%) | 13 (25.4) |
| t (11;14) | 19 (14.3%) | 10 (12.2%) | 9 (10.9%) |
| t (14;16) | 5 (3.75%) | 3 (3.65%) | 2 (3.92%) |
| del13q,del17p | 50 (37.6%) | 32 (39%) | 18 (35.3%) |
| R-ISS stage | |||
| I | 35 (26.3%) | 26 (31.7%) | 9 (17.6%) |
| II | 47 (35.3%) | 27 (32.9%) | 20 (39.2%) |
| III | 51 (38s.3%) | 19 (23.2%) | 32 (62.7%) |
| Induction or maintenance regimen | |||
| VD | 11 (8.3%) | 11 (13.4%) | 0 (0) |
| VCD | 93 (69.9%) | 62 (75.6%) | 31 (60.8%) |
| VTD | 29 (21.8%) | 9 (11%) | 20 (39.2%) |
NDMM newly diagnosed MM, rrMM refractory or relapsed MM, BD bortezomib, dexamethasone, BCD bortezomib, dexamethasone, cyclophosphamide, VTD bortezomib, thalidomide, dexamethasone
aThe status of 1 patient is unknown